JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2198634, encodeId=a82d219863411, content=偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3投稿，4.4peer review，到现在还是这个状态，是不是要拒稿的意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:46:53 CST 2024, time=昨天, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198633, encodeId=5897219863300, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3提交，到现在状态还是peer review，这个是不是要拒稿的意思啊，要不要催一下呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:42:11 CST 2024, time=昨天, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197232, encodeId=551a219e23241, content=记录一下，bulk+单细胞纯生信一篇 Submission under peer review 30 Mar 2024 Submission passed technical check 30 Mar 2024 Submission is under technical check 29 Mar 2024 Submission received 29 Mar 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19d5694575, createdName=ms6000001440282685, createdTime=Sun Apr 07 12:27:47 CST 2024, time=2024-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=480, replyNumber=125, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192743, encodeId=01e12192e4309, content=二战这个杂志，去年5月投了篇临床预测模型seer数据库文章，大修后拒稿。这次又投了篇机器学习。不过感觉审稿速度慢了好多 3 Mar initial technical check 4 Mar technical check passed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Tue Mar 12 13:06:33 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2195480, encodeId=7e252195480ef, content=求问各位已经proof的大神，接收后一般多久能proof呀？accept是3.11，到现在都没有消息，有些紧张……提前感谢各位大神的解答！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5e08675679, createdName=ms6000000287967542, createdTime=Tue Mar 26 18:56:08 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2191590, encodeId=dce6219159003, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：还是比较快的 Submission is in publishing and rights 05 Mar 2024 Peer review Submission status Date Submission accepted 05 Mar 2024 Submission under peer review 16 Feb 2024 Submission passed technical check 16 Feb 2024 Revision received 15 Feb 2024 Submission under peer review 11 Jan 2024 Technical check Submission status Date Submission passed technical check 11 Jan 2024 Submission is under technical check 10 Jan 2024 Submission received Submission status Date Submission received 10 Jan 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e8382356, createdName=ms5000001486959246, createdTime=Wed Mar 06 21:41:34 CST 2024, time=2024-03-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192970, encodeId=095d21929e092, content=偏重的研究方向：肿瘤临床;肿瘤 经验分享：大神们，The eidtors' decision can take several weeks as they may consult peer reviews.这种状态是审了还是没审啊，2周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Wed Mar 13 15:01:47 CST 2024, time=2024-03-13, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2182701, encodeId=5bfd2182e01db, content=偏重的研究方向：肿瘤 经验分享：记录：生信加验证 23.12.12投稿 24.1.17返两个审稿人意见，都是小修，加起来6条意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cc7c5397146, createdName=ms3000000321226977, createdTime=Fri Jan 19 20:28:23 CST 2024, time=2024-01-19, status=1, ipAttribution=)]

昨天 ms7000001719461797 来自重庆

偏重的研究方向：免疫;肿瘤;生信
经验分享：4.3投稿，4.4peer review，到现在还是这个状态，是不是要拒稿的意思啊

1 0

[GetPortalCommentsPageByObjectIdResponse(id=2198634, encodeId=a82d219863411, content=偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3投稿，4.4peer review，到现在还是这个状态，是不是要拒稿的意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:46:53 CST 2024, time=昨天, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198633, encodeId=5897219863300, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3提交，到现在状态还是peer review，这个是不是要拒稿的意思啊，要不要催一下呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:42:11 CST 2024, time=昨天, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197232, encodeId=551a219e23241, content=记录一下，bulk+单细胞纯生信一篇 Submission under peer review 30 Mar 2024 Submission passed technical check 30 Mar 2024 Submission is under technical check 29 Mar 2024 Submission received 29 Mar 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19d5694575, createdName=ms6000001440282685, createdTime=Sun Apr 07 12:27:47 CST 2024, time=2024-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=480, replyNumber=125, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192743, encodeId=01e12192e4309, content=二战这个杂志，去年5月投了篇临床预测模型seer数据库文章，大修后拒稿。这次又投了篇机器学习。不过感觉审稿速度慢了好多 3 Mar initial technical check 4 Mar technical check passed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Tue Mar 12 13:06:33 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2195480, encodeId=7e252195480ef, content=求问各位已经proof的大神，接收后一般多久能proof呀？accept是3.11，到现在都没有消息，有些紧张……提前感谢各位大神的解答！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5e08675679, createdName=ms6000000287967542, createdTime=Tue Mar 26 18:56:08 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2191590, encodeId=dce6219159003, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：还是比较快的 Submission is in publishing and rights 05 Mar 2024 Peer review Submission status Date Submission accepted 05 Mar 2024 Submission under peer review 16 Feb 2024 Submission passed technical check 16 Feb 2024 Revision received 15 Feb 2024 Submission under peer review 11 Jan 2024 Technical check Submission status Date Submission passed technical check 11 Jan 2024 Submission is under technical check 10 Jan 2024 Submission received Submission status Date Submission received 10 Jan 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e8382356, createdName=ms5000001486959246, createdTime=Wed Mar 06 21:41:34 CST 2024, time=2024-03-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192970, encodeId=095d21929e092, content=偏重的研究方向：肿瘤临床;肿瘤 经验分享：大神们，The eidtors' decision can take several weeks as they may consult peer reviews.这种状态是审了还是没审啊，2周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Wed Mar 13 15:01:47 CST 2024, time=2024-03-13, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2182701, encodeId=5bfd2182e01db, content=偏重的研究方向：肿瘤 经验分享：记录：生信加验证 23.12.12投稿 24.1.17返两个审稿人意见，都是小修，加起来6条意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cc7c5397146, createdName=ms3000000321226977, createdTime=Fri Jan 19 20:28:23 CST 2024, time=2024-01-19, status=1, ipAttribution=)]

昨天 ms7000001719461797 来自重庆

审稿速度:2.0
偏重的研究方向：免疫;肿瘤;生信
经验分享：4.3提交，到现在状态还是peer review，这个是不是要拒稿的意思啊，要不要催一下呢

0 0

[GetPortalCommentsPageByObjectIdResponse(id=2198634, encodeId=a82d219863411, content=偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3投稿，4.4peer review，到现在还是这个状态，是不是要拒稿的意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:46:53 CST 2024, time=昨天, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198633, encodeId=5897219863300, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3提交，到现在状态还是peer review，这个是不是要拒稿的意思啊，要不要催一下呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:42:11 CST 2024, time=昨天, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197232, encodeId=551a219e23241, content=记录一下，bulk+单细胞纯生信一篇 Submission under peer review 30 Mar 2024 Submission passed technical check 30 Mar 2024 Submission is under technical check 29 Mar 2024 Submission received 29 Mar 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19d5694575, createdName=ms6000001440282685, createdTime=Sun Apr 07 12:27:47 CST 2024, time=2024-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=480, replyNumber=125, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192743, encodeId=01e12192e4309, content=二战这个杂志，去年5月投了篇临床预测模型seer数据库文章，大修后拒稿。这次又投了篇机器学习。不过感觉审稿速度慢了好多 3 Mar initial technical check 4 Mar technical check passed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Tue Mar 12 13:06:33 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2195480, encodeId=7e252195480ef, content=求问各位已经proof的大神，接收后一般多久能proof呀？accept是3.11，到现在都没有消息，有些紧张……提前感谢各位大神的解答！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5e08675679, createdName=ms6000000287967542, createdTime=Tue Mar 26 18:56:08 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2191590, encodeId=dce6219159003, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：还是比较快的 Submission is in publishing and rights 05 Mar 2024 Peer review Submission status Date Submission accepted 05 Mar 2024 Submission under peer review 16 Feb 2024 Submission passed technical check 16 Feb 2024 Revision received 15 Feb 2024 Submission under peer review 11 Jan 2024 Technical check Submission status Date Submission passed technical check 11 Jan 2024 Submission is under technical check 10 Jan 2024 Submission received Submission status Date Submission received 10 Jan 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e8382356, createdName=ms5000001486959246, createdTime=Wed Mar 06 21:41:34 CST 2024, time=2024-03-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192970, encodeId=095d21929e092, content=偏重的研究方向：肿瘤临床;肿瘤 经验分享：大神们，The eidtors' decision can take several weeks as they may consult peer reviews.这种状态是审了还是没审啊，2周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Wed Mar 13 15:01:47 CST 2024, time=2024-03-13, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2182701, encodeId=5bfd2182e01db, content=偏重的研究方向：肿瘤 经验分享：记录：生信加验证 23.12.12投稿 24.1.17返两个审稿人意见，都是小修，加起来6条意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cc7c5397146, createdName=ms3000000321226977, createdTime=Fri Jan 19 20:28:23 CST 2024, time=2024-01-19, status=1, ipAttribution=)]

2024-04-07 ms6000001440282685 来自江苏省

记录一下，bulk+单细胞纯生信一篇
Submission under peer review 30 Mar 2024
Submission passed technical check 30 Mar 2024
Submission is under technical check 29 Mar 2024
Submission received 29 Mar 2024

8 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198634, encodeId=a82d219863411, content=偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3投稿，4.4peer review，到现在还是这个状态，是不是要拒稿的意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:46:53 CST 2024, time=昨天, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198633, encodeId=5897219863300, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3提交，到现在状态还是peer review，这个是不是要拒稿的意思啊，要不要催一下呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:42:11 CST 2024, time=昨天, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197232, encodeId=551a219e23241, content=记录一下，bulk+单细胞纯生信一篇 Submission under peer review 30 Mar 2024 Submission passed technical check 30 Mar 2024 Submission is under technical check 29 Mar 2024 Submission received 29 Mar 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19d5694575, createdName=ms6000001440282685, createdTime=Sun Apr 07 12:27:47 CST 2024, time=2024-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=480, replyNumber=125, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192743, encodeId=01e12192e4309, content=二战这个杂志，去年5月投了篇临床预测模型seer数据库文章，大修后拒稿。这次又投了篇机器学习。不过感觉审稿速度慢了好多 3 Mar initial technical check 4 Mar technical check passed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Tue Mar 12 13:06:33 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2195480, encodeId=7e252195480ef, content=求问各位已经proof的大神，接收后一般多久能proof呀？accept是3.11，到现在都没有消息，有些紧张……提前感谢各位大神的解答！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5e08675679, createdName=ms6000000287967542, createdTime=Tue Mar 26 18:56:08 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2191590, encodeId=dce6219159003, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：还是比较快的 Submission is in publishing and rights 05 Mar 2024 Peer review Submission status Date Submission accepted 05 Mar 2024 Submission under peer review 16 Feb 2024 Submission passed technical check 16 Feb 2024 Revision received 15 Feb 2024 Submission under peer review 11 Jan 2024 Technical check Submission status Date Submission passed technical check 11 Jan 2024 Submission is under technical check 10 Jan 2024 Submission received Submission status Date Submission received 10 Jan 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e8382356, createdName=ms5000001486959246, createdTime=Wed Mar 06 21:41:34 CST 2024, time=2024-03-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192970, encodeId=095d21929e092, content=偏重的研究方向：肿瘤临床;肿瘤 经验分享：大神们，The eidtors' decision can take several weeks as they may consult peer reviews.这种状态是审了还是没审啊，2周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Wed Mar 13 15:01:47 CST 2024, time=2024-03-13, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2182701, encodeId=5bfd2182e01db, content=偏重的研究方向：肿瘤 经验分享：记录：生信加验证 23.12.12投稿 24.1.17返两个审稿人意见，都是小修，加起来6条意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cc7c5397146, createdName=ms3000000321226977, createdTime=Fri Jan 19 20:28:23 CST 2024, time=2024-01-19, status=1, ipAttribution=)]

2020-06-12 ms5502585941462392

9月28投稿，10月7日直接接收，还以为是拒稿。😀

480 125

展开125条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198634, encodeId=a82d219863411, content=偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3投稿，4.4peer review，到现在还是这个状态，是不是要拒稿的意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:46:53 CST 2024, time=昨天, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198633, encodeId=5897219863300, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3提交，到现在状态还是peer review，这个是不是要拒稿的意思啊，要不要催一下呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:42:11 CST 2024, time=昨天, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197232, encodeId=551a219e23241, content=记录一下，bulk+单细胞纯生信一篇 Submission under peer review 30 Mar 2024 Submission passed technical check 30 Mar 2024 Submission is under technical check 29 Mar 2024 Submission received 29 Mar 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19d5694575, createdName=ms6000001440282685, createdTime=Sun Apr 07 12:27:47 CST 2024, time=2024-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=480, replyNumber=125, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192743, encodeId=01e12192e4309, content=二战这个杂志，去年5月投了篇临床预测模型seer数据库文章，大修后拒稿。这次又投了篇机器学习。不过感觉审稿速度慢了好多 3 Mar initial technical check 4 Mar technical check passed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Tue Mar 12 13:06:33 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2195480, encodeId=7e252195480ef, content=求问各位已经proof的大神，接收后一般多久能proof呀？accept是3.11，到现在都没有消息，有些紧张……提前感谢各位大神的解答！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5e08675679, createdName=ms6000000287967542, createdTime=Tue Mar 26 18:56:08 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2191590, encodeId=dce6219159003, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：还是比较快的 Submission is in publishing and rights 05 Mar 2024 Peer review Submission status Date Submission accepted 05 Mar 2024 Submission under peer review 16 Feb 2024 Submission passed technical check 16 Feb 2024 Revision received 15 Feb 2024 Submission under peer review 11 Jan 2024 Technical check Submission status Date Submission passed technical check 11 Jan 2024 Submission is under technical check 10 Jan 2024 Submission received Submission status Date Submission received 10 Jan 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e8382356, createdName=ms5000001486959246, createdTime=Wed Mar 06 21:41:34 CST 2024, time=2024-03-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192970, encodeId=095d21929e092, content=偏重的研究方向：肿瘤临床;肿瘤 经验分享：大神们，The eidtors' decision can take several weeks as they may consult peer reviews.这种状态是审了还是没审啊，2周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Wed Mar 13 15:01:47 CST 2024, time=2024-03-13, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2182701, encodeId=5bfd2182e01db, content=偏重的研究方向：肿瘤 经验分享：记录：生信加验证 23.12.12投稿 24.1.17返两个审稿人意见，都是小修，加起来6条意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cc7c5397146, createdName=ms3000000321226977, createdTime=Fri Jan 19 20:28:23 CST 2024, time=2024-01-19, status=1, ipAttribution=)]

2024-03-12 ms6000001537745536 来自四川省

二战这个杂志，去年5月投了篇临床预测模型seer数据库文章，大修后拒稿。这次又投了篇机器学习。不过感觉审稿速度慢了好多 3 Mar initial technical check 4 Mar technical check passed

13 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198634, encodeId=a82d219863411, content=偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3投稿，4.4peer review，到现在还是这个状态，是不是要拒稿的意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:46:53 CST 2024, time=昨天, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198633, encodeId=5897219863300, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3提交，到现在状态还是peer review，这个是不是要拒稿的意思啊，要不要催一下呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:42:11 CST 2024, time=昨天, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197232, encodeId=551a219e23241, content=记录一下，bulk+单细胞纯生信一篇 Submission under peer review 30 Mar 2024 Submission passed technical check 30 Mar 2024 Submission is under technical check 29 Mar 2024 Submission received 29 Mar 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19d5694575, createdName=ms6000001440282685, createdTime=Sun Apr 07 12:27:47 CST 2024, time=2024-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=480, replyNumber=125, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192743, encodeId=01e12192e4309, content=二战这个杂志，去年5月投了篇临床预测模型seer数据库文章，大修后拒稿。这次又投了篇机器学习。不过感觉审稿速度慢了好多 3 Mar initial technical check 4 Mar technical check passed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Tue Mar 12 13:06:33 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2195480, encodeId=7e252195480ef, content=求问各位已经proof的大神，接收后一般多久能proof呀？accept是3.11，到现在都没有消息，有些紧张……提前感谢各位大神的解答！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5e08675679, createdName=ms6000000287967542, createdTime=Tue Mar 26 18:56:08 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2191590, encodeId=dce6219159003, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：还是比较快的 Submission is in publishing and rights 05 Mar 2024 Peer review Submission status Date Submission accepted 05 Mar 2024 Submission under peer review 16 Feb 2024 Submission passed technical check 16 Feb 2024 Revision received 15 Feb 2024 Submission under peer review 11 Jan 2024 Technical check Submission status Date Submission passed technical check 11 Jan 2024 Submission is under technical check 10 Jan 2024 Submission received Submission status Date Submission received 10 Jan 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e8382356, createdName=ms5000001486959246, createdTime=Wed Mar 06 21:41:34 CST 2024, time=2024-03-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192970, encodeId=095d21929e092, content=偏重的研究方向：肿瘤临床;肿瘤 经验分享：大神们，The eidtors' decision can take several weeks as they may consult peer reviews.这种状态是审了还是没审啊，2周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Wed Mar 13 15:01:47 CST 2024, time=2024-03-13, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2182701, encodeId=5bfd2182e01db, content=偏重的研究方向：肿瘤 经验分享：记录：生信加验证 23.12.12投稿 24.1.17返两个审稿人意见，都是小修，加起来6条意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cc7c5397146, createdName=ms3000000321226977, createdTime=Fri Jan 19 20:28:23 CST 2024, time=2024-01-19, status=1, ipAttribution=)]

2024-03-26 ms6000000287967542 来自浙江省

求问各位已经proof的大神，接收后一般多久能proof呀？accept是3.11，到现在都没有消息，有些紧张……提前感谢各位大神的解答！

8 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198634, encodeId=a82d219863411, content=偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3投稿，4.4peer review，到现在还是这个状态，是不是要拒稿的意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:46:53 CST 2024, time=昨天, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198633, encodeId=5897219863300, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3提交，到现在状态还是peer review，这个是不是要拒稿的意思啊，要不要催一下呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:42:11 CST 2024, time=昨天, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197232, encodeId=551a219e23241, content=记录一下，bulk+单细胞纯生信一篇 Submission under peer review 30 Mar 2024 Submission passed technical check 30 Mar 2024 Submission is under technical check 29 Mar 2024 Submission received 29 Mar 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19d5694575, createdName=ms6000001440282685, createdTime=Sun Apr 07 12:27:47 CST 2024, time=2024-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=480, replyNumber=125, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192743, encodeId=01e12192e4309, content=二战这个杂志，去年5月投了篇临床预测模型seer数据库文章，大修后拒稿。这次又投了篇机器学习。不过感觉审稿速度慢了好多 3 Mar initial technical check 4 Mar technical check passed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Tue Mar 12 13:06:33 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2195480, encodeId=7e252195480ef, content=求问各位已经proof的大神，接收后一般多久能proof呀？accept是3.11，到现在都没有消息，有些紧张……提前感谢各位大神的解答！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5e08675679, createdName=ms6000000287967542, createdTime=Tue Mar 26 18:56:08 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2191590, encodeId=dce6219159003, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：还是比较快的 Submission is in publishing and rights 05 Mar 2024 Peer review Submission status Date Submission accepted 05 Mar 2024 Submission under peer review 16 Feb 2024 Submission passed technical check 16 Feb 2024 Revision received 15 Feb 2024 Submission under peer review 11 Jan 2024 Technical check Submission status Date Submission passed technical check 11 Jan 2024 Submission is under technical check 10 Jan 2024 Submission received Submission status Date Submission received 10 Jan 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e8382356, createdName=ms5000001486959246, createdTime=Wed Mar 06 21:41:34 CST 2024, time=2024-03-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192970, encodeId=095d21929e092, content=偏重的研究方向：肿瘤临床;肿瘤 经验分享：大神们，The eidtors' decision can take several weeks as they may consult peer reviews.这种状态是审了还是没审啊，2周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Wed Mar 13 15:01:47 CST 2024, time=2024-03-13, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2182701, encodeId=5bfd2182e01db, content=偏重的研究方向：肿瘤 经验分享：记录：生信加验证 23.12.12投稿 24.1.17返两个审稿人意见，都是小修，加起来6条意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cc7c5397146, createdName=ms3000000321226977, createdTime=Fri Jan 19 20:28:23 CST 2024, time=2024-01-19, status=1, ipAttribution=)]

2024-03-06 ms5000001486959246 来自北京

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤
经验分享：还是比较快的
Submission is in publishing and rights
05 Mar 2024
Peer review
Submission status Date
Submission accepted
05 Mar 2024
Submission under peer review
16 Feb 2024
Submission passed technical check
16 Feb 2024
Revision received
15 Feb 2024
Submission under peer review
11 Jan 2024
Technical check
Submission status Date
Submission passed technical check
11 Jan 2024
Submission is under technical check
10 Jan 2024
Submission received
Submission status Date
Submission received
10 Jan 2024

15 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198634, encodeId=a82d219863411, content=偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3投稿，4.4peer review，到现在还是这个状态，是不是要拒稿的意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:46:53 CST 2024, time=昨天, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198633, encodeId=5897219863300, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3提交，到现在状态还是peer review，这个是不是要拒稿的意思啊，要不要催一下呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:42:11 CST 2024, time=昨天, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197232, encodeId=551a219e23241, content=记录一下，bulk+单细胞纯生信一篇 Submission under peer review 30 Mar 2024 Submission passed technical check 30 Mar 2024 Submission is under technical check 29 Mar 2024 Submission received 29 Mar 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19d5694575, createdName=ms6000001440282685, createdTime=Sun Apr 07 12:27:47 CST 2024, time=2024-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=480, replyNumber=125, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192743, encodeId=01e12192e4309, content=二战这个杂志，去年5月投了篇临床预测模型seer数据库文章，大修后拒稿。这次又投了篇机器学习。不过感觉审稿速度慢了好多 3 Mar initial technical check 4 Mar technical check passed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Tue Mar 12 13:06:33 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2195480, encodeId=7e252195480ef, content=求问各位已经proof的大神，接收后一般多久能proof呀？accept是3.11，到现在都没有消息，有些紧张……提前感谢各位大神的解答！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5e08675679, createdName=ms6000000287967542, createdTime=Tue Mar 26 18:56:08 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2191590, encodeId=dce6219159003, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：还是比较快的 Submission is in publishing and rights 05 Mar 2024 Peer review Submission status Date Submission accepted 05 Mar 2024 Submission under peer review 16 Feb 2024 Submission passed technical check 16 Feb 2024 Revision received 15 Feb 2024 Submission under peer review 11 Jan 2024 Technical check Submission status Date Submission passed technical check 11 Jan 2024 Submission is under technical check 10 Jan 2024 Submission received Submission status Date Submission received 10 Jan 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e8382356, createdName=ms5000001486959246, createdTime=Wed Mar 06 21:41:34 CST 2024, time=2024-03-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192970, encodeId=095d21929e092, content=偏重的研究方向：肿瘤临床;肿瘤 经验分享：大神们，The eidtors' decision can take several weeks as they may consult peer reviews.这种状态是审了还是没审啊，2周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Wed Mar 13 15:01:47 CST 2024, time=2024-03-13, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2182701, encodeId=5bfd2182e01db, content=偏重的研究方向：肿瘤 经验分享：记录：生信加验证 23.12.12投稿 24.1.17返两个审稿人意见，都是小修，加起来6条意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cc7c5397146, createdName=ms3000000321226977, createdTime=Fri Jan 19 20:28:23 CST 2024, time=2024-01-19, status=1, ipAttribution=)]

2024-03-13 ms9000000002911795 来自黑龙江省

偏重的研究方向：肿瘤临床;肿瘤
经验分享：大神们，The eidtors' decision can take several weeks as they may consult peer reviews.这种状态是审了还是没审啊，2周了

9 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198634, encodeId=a82d219863411, content=偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3投稿，4.4peer review，到现在还是这个状态，是不是要拒稿的意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:46:53 CST 2024, time=昨天, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198633, encodeId=5897219863300, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3提交，到现在状态还是peer review，这个是不是要拒稿的意思啊，要不要催一下呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:42:11 CST 2024, time=昨天, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197232, encodeId=551a219e23241, content=记录一下，bulk+单细胞纯生信一篇 Submission under peer review 30 Mar 2024 Submission passed technical check 30 Mar 2024 Submission is under technical check 29 Mar 2024 Submission received 29 Mar 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19d5694575, createdName=ms6000001440282685, createdTime=Sun Apr 07 12:27:47 CST 2024, time=2024-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=480, replyNumber=125, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192743, encodeId=01e12192e4309, content=二战这个杂志，去年5月投了篇临床预测模型seer数据库文章，大修后拒稿。这次又投了篇机器学习。不过感觉审稿速度慢了好多 3 Mar initial technical check 4 Mar technical check passed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Tue Mar 12 13:06:33 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2195480, encodeId=7e252195480ef, content=求问各位已经proof的大神，接收后一般多久能proof呀？accept是3.11，到现在都没有消息，有些紧张……提前感谢各位大神的解答！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5e08675679, createdName=ms6000000287967542, createdTime=Tue Mar 26 18:56:08 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2191590, encodeId=dce6219159003, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：还是比较快的 Submission is in publishing and rights 05 Mar 2024 Peer review Submission status Date Submission accepted 05 Mar 2024 Submission under peer review 16 Feb 2024 Submission passed technical check 16 Feb 2024 Revision received 15 Feb 2024 Submission under peer review 11 Jan 2024 Technical check Submission status Date Submission passed technical check 11 Jan 2024 Submission is under technical check 10 Jan 2024 Submission received Submission status Date Submission received 10 Jan 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e8382356, createdName=ms5000001486959246, createdTime=Wed Mar 06 21:41:34 CST 2024, time=2024-03-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192970, encodeId=095d21929e092, content=偏重的研究方向：肿瘤临床;肿瘤 经验分享：大神们，The eidtors' decision can take several weeks as they may consult peer reviews.这种状态是审了还是没审啊，2周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Wed Mar 13 15:01:47 CST 2024, time=2024-03-13, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2182701, encodeId=5bfd2182e01db, content=偏重的研究方向：肿瘤 经验分享：记录：生信加验证 23.12.12投稿 24.1.17返两个审稿人意见，都是小修，加起来6条意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cc7c5397146, createdName=ms3000000321226977, createdTime=Fri Jan 19 20:28:23 CST 2024, time=2024-01-19, status=1, ipAttribution=)]

2023-05-13 wwei0125 来自山东省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志

63 25

展开25条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198634, encodeId=a82d219863411, content=偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3投稿，4.4peer review，到现在还是这个状态，是不是要拒稿的意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:46:53 CST 2024, time=昨天, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198633, encodeId=5897219863300, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤;生信 经验分享：4.3提交，到现在状态还是peer review，这个是不是要拒稿的意思啊，要不要催一下呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2458147977, createdName=ms7000001719461797, createdTime=Mon Apr 15 16:42:11 CST 2024, time=昨天, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197232, encodeId=551a219e23241, content=记录一下，bulk+单细胞纯生信一篇 Submission under peer review 30 Mar 2024 Submission passed technical check 30 Mar 2024 Submission is under technical check 29 Mar 2024 Submission received 29 Mar 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19d5694575, createdName=ms6000001440282685, createdTime=Sun Apr 07 12:27:47 CST 2024, time=2024-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=480, replyNumber=125, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192743, encodeId=01e12192e4309, content=二战这个杂志，去年5月投了篇临床预测模型seer数据库文章，大修后拒稿。这次又投了篇机器学习。不过感觉审稿速度慢了好多 3 Mar initial technical check 4 Mar technical check passed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Tue Mar 12 13:06:33 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2195480, encodeId=7e252195480ef, content=求问各位已经proof的大神，接收后一般多久能proof呀？accept是3.11，到现在都没有消息，有些紧张……提前感谢各位大神的解答！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5e08675679, createdName=ms6000000287967542, createdTime=Tue Mar 26 18:56:08 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2191590, encodeId=dce6219159003, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：还是比较快的 Submission is in publishing and rights 05 Mar 2024 Peer review Submission status Date Submission accepted 05 Mar 2024 Submission under peer review 16 Feb 2024 Submission passed technical check 16 Feb 2024 Revision received 15 Feb 2024 Submission under peer review 11 Jan 2024 Technical check Submission status Date Submission passed technical check 11 Jan 2024 Submission is under technical check 10 Jan 2024 Submission received Submission status Date Submission received 10 Jan 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e8382356, createdName=ms5000001486959246, createdTime=Wed Mar 06 21:41:34 CST 2024, time=2024-03-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192970, encodeId=095d21929e092, content=偏重的研究方向：肿瘤临床;肿瘤 经验分享：大神们，The eidtors' decision can take several weeks as they may consult peer reviews.这种状态是审了还是没审啊，2周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Wed Mar 13 15:01:47 CST 2024, time=2024-03-13, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2182701, encodeId=5bfd2182e01db, content=偏重的研究方向：肿瘤 经验分享：记录：生信加验证 23.12.12投稿 24.1.17返两个审稿人意见，都是小修，加起来6条意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cc7c5397146, createdName=ms3000000321226977, createdTime=Fri Jan 19 20:28:23 CST 2024, time=2024-01-19, status=1, ipAttribution=)]

2024-01-19 ms3000000321226977

偏重的研究方向：肿瘤
经验分享：记录：生信加验证 23.12.12投稿 24.1.17返两个审稿人意见，都是小修，加起来6条意见

60 12

展开12条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务